22
Participants
Start Date
June 30, 2012
Primary Completion Date
February 28, 2014
Study Completion Date
August 31, 2014
OIS (Oxaliplatin, Irinotecan, S-1)
"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
Hallym University Medical Center, Anyang
Collaborators (4)
Jeil Pharmaceutical Co., Ltd.
INDUSTRY
HK inno.N Corporation
INDUSTRY
Pfizer
INDUSTRY
Handok Inc.
INDUSTRY
Hallym University Medical Center
OTHER